Future prospectives for the management of chronic hepatitis B

Table 2 Treatment outcomes after 1 year of treatment for different antiviral drugs for the management of chronic hepatitis B

	Author; Journal; Year	HBeAgloss (%)	HBeAg seroconversion(%)	HBsAgloss (%)	Decline viral load (log10 copies/mL)	HBV DNAnegativity(%)	ALT normalisation (%)	Histological improvement (%)	Resistance (%)
HBeAg pos
PEG-IFN-α 2a	Cooksley; J. Viral Hepatitis; 2003[18]	35	33			399	35
PEG-IFN-α 2a	Lau: NEJM; 2005[4]	34	32	312	2.4	144	41	49
PEG-IFN-α 2b	Janssen; Lancet; 2005[3]	36	29	7	2.3	74	32	5310
Lamivudine	Chang; NEJM; 2006[13]	20	18	1	5.4	362	60	62	13
Lamivudine	Alexander; BMC Gastroenter; 2005[150]	42	28				56		10
Lamivudine	Chan; Ann Intern Med; 2005[151]	28	28	0	2.74	101	78	5911	40
Lamivudine	Yao; Hepatobil Pancr Dis Int; 2004[152]	10	8			36	72		12
Lamivudine	Jonas; NEJM; 2002[153]	26		2		616	55		19
Lamivudine	Mazur; Med Sci Monit; 2002[154]	49	44	5		378	56
Lamivudine	Barbaro; J Hepatol: 2001[155]		19	0			23	2710	16
Lamivudine	Dienstag; NEJM 1999[47]	32	17	2		447	41	5210	32
Lamivudine	Gane; J Hepatol; 2006[63]	23	21		5.5	402	75	56	8
Adefovir	Marcelin; NEJM; 2003[16]	24	12		3.6	214	48	53	0
Adefovir	Lee; Hepatology; 2006[102]	14			4.0	295	79		0
Adefovir15	Zheng; Hepatology; 2006[124]	13	8	0	4.5	282	79		0
Adefovir	Bzowej; Hepatology; 2006[65]	20	18		5.7	392	81		2
Entecavir	Chang; NEJM; 2006[13]	22	21	2	6.9	672	68	72	0
Telbivudine	Gane; J Hepatol; 2006[63]	26	22		6.5	602	77	65	3
Telbivudine	Bzowej; Hepatology; 2006[65]	31	27		6.6	582	77		4
HBeAg neg
PEG-IFN-α 2a	Marcellin; NEJM; 2004[5]			4	2.3	194	59	59
Lamivudine	Marcellin; NEJM; 2004[5]			0	4.2	734	73	5814	41
Lamivudine	Lai; NEJM; 2006[15]			0	4.5	722	71	61	6
Lamivudine	Lai; NEJM; 1999		16	0			72	5610	14
Adefovir	Hadzyannis; NEJM; 2003[14]				3.9	514	72	64	0
Entecavir	Lai; NEJM; 2006[15]			0	5.0	902	78	70	0
Mixed
Lamivudine	Ooga; J Gastroenterology; 2004[156]					785	78		16
Lamivudine	Suzuki; Intervirology; 2003[108]	42	28	0		886	86
Lamivudine	Yao; J Hepatology; 2006[64]		18		4.3	432	78
Entecavir	Yao; J Hepatology; 2006[64]		15		5.9	762	90

Although conventional interferon-α is widely used for the treatment of HBV it is not listed as this treatment will be replaced by PEG-interferon-α in the near future. Efficacy measures for PEG-interferon presented are off-treatment responses after 24 wk of follow-up. Studies are organised by HBeAg status and the mixed studies included both HBeAg positive as HBeAg negative patients.

¹LLD 200 copies/mL;

²LLD 300 copies/mL; ³LLD 366 copies/mL;

⁴400 copies/mL;

⁵5.0 × 10³ copies/mL;

⁶7.0 × 10⁵ copies/mL;

⁷1.0 × 10⁶ copies/mL;

⁸1.4 × 10⁶ copies/mL;

⁹5.0 × 10⁶ copies/mL;

¹⁰only improvement of ≥ 2 points in necroinflammation according to Ishak,

¹¹only improvement of ≥ 2 points in necroinflammation according to Knodell,

¹²HBsAg seroconversion, ¹³treatment duration 24 wk,

¹⁴After 24 wk of follow-up, Lamivudine study performed in children,

¹⁵Includes some lamivudine resistant patients.